

**CA 19.9; PANCREATIC
CANCER MARKER, SERUM
(CMIA)**

U/mL

< 37.00

- Note:** 1. This test is not recommended to screen Pancreatic cancer in the general population.
2. False negative / positive results are observed in patients receiving mouse monoclonal antibodies for diagnosis or therapy
3. This assay, regardless of level, should not be interpreted as absolute evidence for the presence or absence of malignant disease. The assay value should be used in conjunction with findings from clinical evaluation and other diagnostic procedures.
4. Persistently elevated CA 19.9 levels are usually indicative of progressive malignant disease and poor therapeutic response

Clinical Use

- An aid in the management of Pancreatic cancer patients
- Monitor the course of disease and predict recurrence in patients with Pancreatic carcinoma

DISEASE	PERCENTAGE POSITIVITY OF CA 19.9
Pancreatic cancer	80
Hepatobiliary cancer	67
Gastric cancer	40-50
Hepatocellular cancer	30-50
Colorectal cancer	30
Breast cancer	15
Pancreatitis	10-20
Benign Gastrointestinal diseases	10-20